Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of VCH-759 monotherapy in hepatitis C infection.

Journal of hepatology - 1 Jul 2009

Cooper Curtis, Lawitz Eric J, Ghali Peter, Rodriguez-Torres Maribel, Anderson Frank H, Lee Samuel S, Bédard Jean, Chauret Nathalie, Thibert Roch, Boivin Isabel, Nicolas Olivier, Proulx Louise

Abstract excerpt

BACKGROUND/AIMS: VCH-759 is a non-nucleoside inhibitor of HCV RNA-dependent polymerase with sub-micromolar IC(50) values versus genotype 1a/1b replicons. METHODS: The antiviral activity, pharmacokinetics and tolerability of VCH-759 administered as monotherapy for 10 days with a 14 day follow-up p...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Carboxylic Acids
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Phenotype

Share to Thiophenes

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 19446909
DOI: 10.1016/j.jhep.2009.03.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19446909-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of VCH-759 monotherapy in hepatitis C infection.PMID 19446909Read ↗

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.Semantic proximity Read ↗

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.Semantic proximity Read ↗

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Semantic proximity Read ↗

92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTIONSemantic proximity Read ↗

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.Semantic proximity Read ↗

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Semantic proximity Read ↗

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.Semantic proximity Read ↗

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.Semantic proximity Read ↗

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusSemantic proximity Read ↗

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.